Overexpression of Her-2 in patients with poorly differentiated carcinoma or poorly differentiated adenocarcinoma of unknown primary site

被引:59
作者
Hainsworth, JD [1 ]
Lennington, WJ [1 ]
Greco, FA [1 ]
机构
[1] Sarah Cannon Canc Ctr, Nashville, TN USA
关键词
D O I
10.1200/JCO.2000.18.3.632
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: To determine the frequency of Her-2 overexpression in patients with poorly differentiated carcinoma or poorly differentiated adenocarcinoma of unknown primary site. Patients and Methods: Tumor specimens from 100 patients with poorly differentiated carcinoma or poorly differentiated adenocarcinoma were stained for the Her-2 protein using the Dako immunohistochemical method. Clinical and pathologic characteristics of patients with and without Her-2 overexpression were compared. Results: Staining for Her-5 overexpression was successful in 94 of 100 patients. Ten (11%) of 94 tumor specimens overexpressed Her-2. Eight of 10 overexpressors had poorly differentiated adenocarcinoma, and all overexpressors had predominant tumor location above the diaphragm, usually in the mediastinum or lungs. Conclusion: Her-5 overexpression occurs in a minority of patients with poorly differentiated carcinoma/ adenocarcinoma of unknown primary site. Because most overexpressors had poorly differentiated adenocarcinoma, further evaluation of patients with adenocarcinoma of unknown primary site is necessary to determine the frequency of Her-5 overexpression in this common subgroup. Evaluation of the efficacy of trastuzumab in Her-2 overexpressors with carcinoma of unknown primary site is indicated. J Clin Oncol 18:632-635. (C) 2000 by American Society of Clinical Oncology.
引用
收藏
页码:632 / 635
页数:4
相关论文
共 21 条
[1]   HER-2/NEU IN NODE-NEGATIVE BREAST-CANCER - PROGNOSTIC-SIGNIFICANCE OF OVEREXPRESSION INFLUENCED BY THE PRESENCE OF INSITU CARCINOMA [J].
ALLRED, DC ;
CLARK, GM ;
TANDON, AK ;
MOLINA, R ;
TORMEY, DC ;
OSBORNE, CK ;
GILCHRIST, KW ;
MANSOUR, EG ;
ABELOFF, M ;
EUDEY, L ;
MCGUIRE, WL .
JOURNAL OF CLINICAL ONCOLOGY, 1992, 10 (04) :599-605
[2]  
COBLEIGH MA, 1998, P AN M AM SOC CLIN, V17, pA97
[3]   TYROSINE KINASE RECEPTOR WITH EXTENSIVE HOMOLOGY TO EGF RECEPTOR SHARES CHROMOSOMAL LOCATION WITH NEU ONCOGENE [J].
COUSSENS, L ;
YANGFENG, TL ;
LIAO, YC ;
CHEN, E ;
GRAY, A ;
MCGRATH, J ;
SEEBURG, PH ;
LIBERMANN, TA ;
SCHLESSINGER, J ;
FRANCKE, U ;
LEVINSON, A ;
ULLRICH, A .
SCIENCE, 1985, 230 (4730) :1132-1139
[4]   CIS-DIAMMINEDICHLOROPLATINUM, VINBLASTINE, AND BLEOMYCIN COMBINATION CHEMOTHERAPY IN DISSEMINATED TESTICULAR CANCER [J].
EINHORN, LH ;
DONOHUE, J .
ANNALS OF INTERNAL MEDICINE, 1977, 87 (03) :293-298
[5]  
ELLERBROEK N, 1990, CANCER, V66, P1481
[6]  
Eltabbakh GH, 1998, ONCOLOGY-NY, V12, P813
[7]   5-FLUOROURACIL, ADRIAMYCIN, AND MITOMYCIN IN THE TREATMENT OF ADENOCARCINOMA OF UNKNOWN PRIMARY [J].
GOLDBERG, RM ;
SMITH, FP ;
UENO, W ;
AHLGREN, JD ;
SCHEIN, PS .
JOURNAL OF CLINICAL ONCOLOGY, 1986, 4 (03) :395-399
[8]  
Greco F. Anthony, 1997, P2423
[9]   ADVANCED POORLY DIFFERENTIATED CARCINOMA OF UNKNOWN PRIMARY SITE - RECOGNITION OF A TREATABLE SYNDROME [J].
GRECO, FA ;
VAUGHN, WK ;
HAINSWORTH, JD .
ANNALS OF INTERNAL MEDICINE, 1986, 104 (04) :547-553
[10]   Carcinoma of unknown primary site: Treatment with 1-hour paclitaxel, carboplatin, and extended-schedule etoposide [J].
Hainsworth, JD ;
Erland, JB ;
Kalman, LA ;
Schreeder, MT ;
Greco, FA .
JOURNAL OF CLINICAL ONCOLOGY, 1997, 15 (06) :2385-2393